p38 mitogen-activated protein kinase (MAPK) regulates
cytokines in
arthritis and is, in turn, regulated by
MAPK kinase (MKK) 3 and MKK6. To modulate p38 function but potentially minimize toxicity, we evaluated the utility of targeting MKK3 by using MKK3(-/-) mice. These studies showed that
TNF-alpha increased phosphorylation of p38 in WT cultured synoviocytes but that p38 activation, IL-1beta, and
IL-6 expression were markedly lower in MKK3(-/-) synoviocytes. In contrast, IL-1beta or LPS-stimulated p38 phosphorylation and
IL-6 production by MKK3(-/-) synoviocytes were normal. Detailed signaling studies showed that
NF-kappaB also contributes to
IL-6 production and that
TNF-alpha-induced
NF-kappaB activation is MKK3-dependent. In contrast, LPS-mediated activation of
NF-kappaB does not require MKK3. To determine whether this dichotomy occurs in vivo, two
inflammation models were studied. In K/BxN passive
arthritis, the severity of
arthritis was dramatically lower in MKK3(-/-) mice. Phospho-p38, phospho-MAPK activator
protein kinase 2, IL-1beta, CXC
ligand 1,
IL-6, and
matrix metalloproteinase (
MMP) 3 levels in the joints of MKK3(-/-) mice were significantly lower than in controls. Exogenous IL-1beta administered during the first 4 days of the passive model restored
arthritis to the same severity as in WT mice. In the second model,
IL-6 production after systemic LPS administration was similar in WT and MKK3(-/-) mice. Therefore, selective MKK3 deficiency can suppress inflammatory
arthritis and
cytokine production while
Toll-like receptor 4-mediated host defense remains intact.